Evotec SE Reports Resilient 9M 2025 Results with Strategic Focus

Evotec SE has released its results for the first nine months of 2025, marked by a revenue of €535.1 million, reflecting a 7.1% decrease. The Discovery & Preclinical Development (D&PD) segment experienced a 12.3% decline, continuing to face challenges in the early drug discovery market. Conversely, Just – Evotec Biologics (JEB) surpassed expectations with an 11.3% revenue growth, propelled by strong non-Sandoz and non-Department of Defense business activities.

A significant highlight was the agreement with Sandoz, promising over $650 million in future payments and royalties from up to ten biosimilar molecules. Evotec also advanced its co-developed asset pipeline, anticipating up to four molecules entering clinical phase II shortly.

Despite facing certain market pressures, Evotec maintains its 2025 guidance with projected revenues between €760-800 million. The company's commitment to strategic partnerships and cost-cutting initiatives remains a core driver, as demonstrated by its collaboration with Bristol Myers Squibb and partners.